Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232676 | 0.88 | BRD4 (0.46) | HCAR3FGFR1HPGDALDH1A1LMNA | |
| SCHEMBL29555937 | 0.84 | FGFR1 (0.45) | HCAR3FGFR1PLA2G4ATBXA2RHPGD | |
| Hydrochloric Acid SCHEMBL30538760 | 0.83 | FGFR1 (0.44) | HCAR3FGFR1PLA2G4ATBXA2RHPGD | |
| SCHEMBL30232780 | 0.78 | CYP11B1 (0.51) | HPGDAPAF1ALDH1A1LMNA | |
| SCHEMBL30686400 | 0.78 | FGFR1 (0.42) | FGFR1PLA2G4ATBXA2R | |
| SCHEMBL30497268 | 0.77 | HCAR3 (0.78) | HCAR3FGFR1HPGDHCAR2ALDH1A1 | |
| SCHEMBL30686407 | 0.77 | FGFR1 (0.48) | HCAR3FGFR1PLA2G4ATBXA2RHPGD | |
| SCHEMBL1528672 | 0.76 | POLB (0.54) | HCAR3FGFR1PLA2G4ATBXA2RHPGD | |
| SCHEMBL30497287 | 0.76 | FGFR1 (0.49) | FGFR1PLA2G4ATBXA2RF2F10 | |
| SCHEMBL31202908 | 0.75 | FGFR1 (0.46) | HCAR3FGFR1PLA2G4ATBXA2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| CN-117242067-B | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4353717-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | Mindrank AI Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117242067-A | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | HCAR3 128/4885FGFR1 53/4885PLA2G4A 3762/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | HCAR3 215/4885FGFR1 210/4885PLA2G4A 4231/4885 |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | HCAR3 126/4885FGFR1 67/4885PLA2G4A 3814/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | HCAR3 122/4885FGFR1 39/4885PLA2G4A 4367/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | HCAR3 108/4885FGFR1 59/4885PLA2G4A 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.